Literature DB >> 8891155

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

R S Schwalbe1, A C McIntosh, S Qaiyumi, J A Johnson, R J Johnson, K M Furness, W J Holloway, L Steele-Moore.   

Abstract

The in vitro activities of LY333328 were compared with those of vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. MICs and MBCs were determined by a microtiter dilution protocol. LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Its potency was comparable or superior to those of other antibiotics tested against methicillin-resistant staphylococci.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8891155      PMCID： PMC163545     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative in-vitro activity of RP 59500 against clinical bacterial isolates.

Authors:  M Inoue; R Okamoto; T Okubo; K Inoue; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

Review 2.  Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors:  C J Hackbarth; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 3.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; R E Stratford; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

5.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate.

Authors:  M K Hayden; G M Trenholme; J E Schultz; D F Sahm
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

7.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

8.  Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

Authors:  R S Schwalbe; W J Ritz; P R Verma; E A Barranco; P H Gilligan
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

9.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  R Leclercq; L Nantas; C J Soussy; J Duval
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790
View more
  23 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

Authors:  F García-Garrote; E Cercenado; L Alcalá; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.

Authors:  H P Endtz; N van den Braak; A van Belkum; J A Kluytmans; J G Koeleman; L Spanjaard; A Voss; A J Weersink; C M Vandenbroucke-Grauls; A G Buiting; A van Duin; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

6.  Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 7.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 10.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.